Matthew Angel, CEO and President, 10% Owner at Tempest Therapeutics, Inc. (TPST), bought 231,482 shares at $2.16 ($500K) on 2026-03-24, disclosed to the SEC on 2026-03-25.
CEO Matthew Angel purchased $500,001 worth of shares at $2.16, marking the largest insider purchase in the company's history. This significant buyback by the CEO during a steep 90% decline suggests confidence in the stock's recovery potential.
The stock has crashed 43.51% over the last 90 days and is down 83.74% year-to-date, trading just 5.14% above its 52-week low of $1.65.
TPST was added to the Zacks Rank #1 (Strong Buy) list on April 10, 2026, providing a potential catalyst for a rebound. Additionally, CEO Matthew Angel executed the largest insider purchase in the company's history, signaling strong conviction in the current valuation.
The company trades at a negative forward P/E of -1.48, indicating ongoing losses. Furthermore, the stock carries a short interest of 6.85% of the float, which could pressure the price if the recovery stalls.
Something here stands out, but not much.